Editas Medicine Inc

NASDAQ:EDITUnited States

Today

Show headlines and story abstract

• Raymond James Downgrades Editas Medicine to Market Perform From Outperform, from 6 hours ago by MT Newswires

  6 hours ago by MT Newswires
  Companies Mentioned: EDIT
  01:49 PM EST, 11/04/2024 (MT Newswires) -- Editas Medicine (EDIT) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $7 to $27. (MT Newswires covers equity, commodity and economic rese...

• Truist Securities Adjusts Editas Medicine's Price Target to $8 From $12, Keeps Buy Rating, from 6 hours ago by MT Newswires

  6 hours ago by MT Newswires
  Companies Mentioned: EDIT
  01:27 PM EST, 11/04/2024 (MT Newswires) -- Editas Medicine (EDIT) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $7 to $27. (MT Newswires covers equity, commodity and economic rese...

• Editas Medicine Announces Third Quarter 2024 Results and Business Updates, from 12 hours ago by Dow Jones

  12 hours ago by Dow Jones
  Companies Mentioned: EDIT
  
  This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements regarding the Company's intent to partner or out-license reni-cel and any benefits resulting therefrom, the initiation, timing, progress and results of the Company's preclinical and clinical studies and its research and development programs, the timing for the Company's receipt and presentation of data from its clinical trials and preclinical studies, including providing an update on its in vivo progress and pipeline development in the first quarter of 2025 and presenting additional clinical data from the RUBY trial at the ASH Annual Meeting and Exposition and from the EdiTHAL trial by year-end 2024, the potential of, and expectations for, the Company's product candidates, including any in vivo gene edited medicines the Company may develop, the timing or likelihood of regulatory filings and approvals, and the Company's expectations regarding cash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of pre-clinical studies and clinical trials, including the RUBY and EdiTHAL trials, and clinical development of the Company's product candidates, including reni-cel; availability and timing of results from pre-clinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption "Risk Factors" included in the Company's most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company's subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the Company explicitly disclaims any obligation to update any forward-looking statements.
  

• *DJ Editas Medicine 3Q Loss/Shr 75c >EDIT, from 12 hours ago by Dow Jones

  12 hours ago by Dow Jones
  Companies Mentioned: EDIT